Prognostic value of cardiovascular magnetic resonance T1 mapping and extracellular volume fraction in nonischemic dilated cardiomyopathy
暂无分享,去创建一个
P. Croisille | S. Rapacchi | A. Lalande | M. Guye | E. Donal | F. Bauer | G. Leurent | F. Roubille | A. Furber | F. Thuny | F. Delahaye | A. Jacquier | G. Habib | J. Dacher | M. Bernard | L. Mangin | J. Eicher | S. Cortaredona | N. Ferrier | R. Giorgi | Serge Willoteaux | L. Bière | F. Tradi | Z. Bentatou | A. Bartoli | F. Cadour | H. Kovacsik | Morgane Quemeneur | P. Lentz | Stephanie M. Biene
[1] P. Lambiase,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. , 2022, European heart journal.
[2] Christopher A. Miller,et al. Extracellular volume fraction improves risk-stratification for ventricular arrhythmias and sudden death in non-ischaemic cardiomyopathy. , 2022, European heart journal. Cardiovascular Imaging.
[3] P. Banys,et al. Extracellular volume is an independent predictor of arrhythmic burden in dilated cardiomyopathy , 2021, Scientific Reports.
[4] A. Arai,et al. T1 Mapping and Extracellular Volume Fraction in Dilated Cardiomyopathy: A Prognosis Study. , 2021, JACC. Cardiovascular imaging.
[5] Christopher A. Miller,et al. Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy. , 2021, Journal of the American College of Cardiology.
[6] S. Rapacchi,et al. Quantification of diffuse myocardial fibrosis using CMR extracellular volume fraction and serum biomarkers of collagen turnover with histologic quantification as standard of reference. , 2020, Diagnostic and interventional imaging.
[7] A. Coats,et al. Heart failure in dilated non-ischaemic cardiomyopathy , 2019, European heart journal supplements : journal of the European Society of Cardiology.
[8] M. Dweck,et al. Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis , 2019, JACC. Cardiovascular imaging.
[9] Reza Nezafat,et al. Correction to: Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) , 2018, Journal of Cardiovascular Magnetic Resonance.
[10] Sven Kabus,et al. Cardiac magnetic resonance T1 and extracellular volume mapping with motion correction and co-registration based on fast elastic image registration , 2017, Magnetic Resonance Materials in Physics, Biology and Medicine.
[11] H. Lee,et al. Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study , 2017, European Radiology.
[12] C. Colak,et al. The evaluation of non-ischemic dilated cardiomyopathy with T1 mapping and ECV methods using 3T cardiac MRI , 2017, La radiologia medica.
[13] P. Ponikowski,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[14] V. Fuster,et al. The MOGE(S) classification of cardiomyopathy for clinicians. , 2014, Journal of the American College of Cardiology.
[15] P. Kellman,et al. T1-mapping in the heart: accuracy and precision , 2014, Journal of Cardiovascular Magnetic Resonance.
[16] W. Stevenson,et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. , 2013, JACC. Cardiovascular imaging.
[17] D. Hedges,et al. Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.
[18] Tevfik F Ismail,et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.
[19] M. Hayward,et al. Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.
[20] Michael Jerosch-Herold,et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. , 2008, American journal of physiology. Heart and circulatory physiology.
[21] Eloisa Arbustini,et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.
[22] Dudley J Pennell,et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.
[23] James A. White,et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. , 2017, JACC. Heart failure.
[24] E. Nagel,et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. , 2016, JACC. Cardiovascular imaging.
[25] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.
[26] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..